Compare Stocks

→ He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COS Canadian Oil Sands		C$0.00	C$5.61 ▼ C$13.87	N/A	N/A	2.19 million shs	N/A
GSD Global System Dynamics	$11.11	$11.16	$9.90 ▼ $11.98	$36.77M	N/A	7,280 shs	2 shs
KNE Kane Biotech	C$0.13 +4.0%	C$0.11	C$0.05 ▼ C$0.17	C$17.14M	0.56	152,713 shs	12,000 shs
OKYO OKYO Pharma	$1.41 +0.7%	$1.44	$0.92 ▼ $3.25	$40.65M	0.04	26,610 shs	50,202 shs

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSD Global System Dynamics	0.00%	0.00%	0.00%	-1.24%	+5.61%
KNE Kane Biotech	-3.85%	0.00%	+25.00%	+47.06%	+4.17%
OKYO OKYO Pharma	-1.40%	0.00%	-3.42%	-10.76%	+10.16%

Thousands of investors use this no cost solution | Do you? (Ad)

In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.

Simply tap here now to subscribe and start getting "Insider Financial Advantage"

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COS Canadian Oil Sands	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GSD Global System Dynamics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KNE Kane Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	1.668 of 5 stars	3.5	3.0	0.0	0.0	0.6	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COS Canadian Oil Sands	3.00	Buy	C$0.52	∞ Upside
GSD Global System Dynamics	N/A	N/A	N/A	N/A
KNE Kane Biotech	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	3.00	Buy	$7.00	396.45% Upside

Current Analyst Ratings

Latest COS, KNE, GSD, OKYO, and HVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/23/2024	COS Canadian Oil Sands	Fundamental Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy	C$0.52
3/22/2024	OKYO OKYO Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COS Canadian Oil Sands	N/A	N/A	N/A	N/A	N/A	N/A
GSD Global System Dynamics	N/A	N/A	N/A	N/A	($1.84) per share	N/A
KNE Kane Biotech	C$2.74M	6.26	C$0.02 per share	8.50	C($0.07) per share	-1.86
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.08) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COS Canadian Oil Sands	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
GSD Global System Dynamics	-$790K	N/A	0.00	∞	N/A	N/A	N/A	-2.30%	N/A
KNE Kane Biotech	-C$4.32M	-C$0.03	N/A	∞	N/A	-157.48%	N/A	-32.70%	5/23/2024 (Estimated)
OKYO OKYO Pharma	-$13.27M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/20/2024 (Estimated)

Latest COS, KNE, GSD, OKYO, and HVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/26/2024	Q4 2023	KNE Kane Biotech	N/A	-C$0.01	-C$0.01	-C$0.01	N/A	C$0.04 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COS Canadian Oil Sands	N/A	N/A	N/A	N/A	N/A
GSD Global System Dynamics	N/A	N/A	N/A	N/A	N/A
KNE Kane Biotech	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COS Canadian Oil Sands	N/A	N/A	N/A
GSD Global System Dynamics	N/A	0.01	0.01
KNE Kane Biotech	1,164.24	0.37	0.39
OKYO OKYO Pharma	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
COS Canadian Oil Sands	N/A
GSD Global System Dynamics	24.82%
KNE Kane Biotech	N/A
OKYO OKYO Pharma	2.97%

Insider Ownership

Company	Insider Ownership
COS Canadian Oil Sands	N/A
GSD Global System Dynamics	62.81%
KNE Kane Biotech	36.45%
OKYO OKYO Pharma	40.46%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
COS Canadian Oil Sands	147,000	N/A	N/A	Not Optionable
GSD Global System Dynamics	N/A	3.31 million	1.23 million	Not Optionable
KNE Kane Biotech	N/A	131.84 million	N/A	Not Optionable
OKYO OKYO Pharma	8	28.83 million	17.17 million	Not Optionable

COS, KNE, GSD, OKYO, and HVO Headlines

Source	Headline
	OKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader event proactiveinvestors.com - April 9 at 8:39 AM
	OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 globenewswire.com - April 8 at 7:00 PM
$OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery$	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery globenewswire.com - April 2 at 7:00 AM
	Japan authorities inspect second Kobayashi Pharma factory after deaths msn.com - March 31 at 9:46 PM
	Japan dietary supplement maker probes five deaths msn.com - March 29 at 8:56 AM
	Analysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX) and Genmab (GMAB) markets.businessinsider.com - March 27 at 6:32 PM
	OKYO Pharma gains after positive results from Phase 2 dry eye disease trial msn.com - March 22 at 3:14 PM
	Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study msn.com - March 22 at 3:14 PM
	OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms proactiveinvestors.com - March 22 at 8:52 AM
	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 globenewswire.com - March 22 at 7:00 AM
	OKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye disease proactiveinvestors.com - March 21 at 9:23 AM
	OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial globenewswire.com - March 21 at 7:00 AM
	OKYO Pharma to release Phase 2 dry eye disease trial results on Friday proactiveinvestors.com - March 20 at 8:55 AM
	OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event globenewswire.com - March 20 at 7:00 AM
	OKYO Pharma Limited (OKYO) Stock Price, News, Quote & History - Yahoo Finance finance.yahoo.com - March 19 at 11:17 AM
	Tokyo stocks open lower as gains locked in, BOJ outcome awaited msn.com - March 19 at 1:09 AM
	OKYO Pharma (OKYO) Price Target Increased by 20.00% to 6.12 msn.com - February 25 at 8:55 AM
	Tokyo stocks open flat as gains locked in, exporters rise msn.com - February 20 at 1:07 PM
	OKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trial proactiveinvestors.com - February 9 at 8:47 AM
	OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain finance.yahoo.com - February 9 at 8:00 AM
	Pulling plug on Aduhelm in AD, Biogen turns resources to Leqembi bioworld.com - February 2 at 1:16 PM
	Stock market today: Asian shares mostly rise after Wall Street rebounds led by tech stocks msn.com - February 2 at 1:16 PM
	OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board finance.yahoo.com - January 31 at 8:20 AM
	Eagles files lawsuit in patent dispute over cancer therapy msn.com - January 18 at 9:32 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PVH Stock Gets 25% Discount: Is Now the Time to Buy?
April 2, 2024 11:25 AM
View PVH Stock Gets 25% Discount: Is Now the Time to Buy?
It’s Time to Buy Into the Super Micro Computer Stock Implosion
April 22, 2024 12:33 PM
View It’s Time to Buy Into the Super Micro Computer Stock Implosion
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
April 12, 2024 7:32 AM
View 2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
The Bottom is in For Tesla: Read This Before Buying the Bounce
April 24, 2024 8:45 AM
View The Bottom is in For Tesla: Read This Before Buying the Bounce
Is Estée Lauder on the Verge Of a Massive Comeback?
April 4, 2024 11:10 AM
View Is Estée Lauder on the Verge Of a Massive Comeback?

All Headlines

Company Descriptions

Canadian Oil Sands

TSE:COS

Canadian Oil Sands Limited is a Canada-based investment company. The Company owns a 36.74% interest in the Syncrude Joint Venture (Syncrude), a producer of low sulphur, light, synthetic crude oil (SCO). Syncrude is involved in the mining and upgrading of bitumen from oil sands near Fort McMurray in northern Alberta. The Syncrude Project is comprised of open-pit oil sands mines, utilities plants, bitumen extraction plants and an upgrading complex that processes bitumen into SCO. Syncrude's leases are located in the Athabasca oil sands deposit. Syncrude produces SCO by mining oil sands, extracting the bitumen from the sands, upgrading the recovered bitumen into lighter oil fractions and combining those fractions into a single SCO product.

Global System Dynamics

NASDAQ:GSD

Global System Dynamics, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company focuses its search on the farming and national security sectors, including farming related operations and businesses that support the farming industry. The company was formerly known as Gladstone Acquisition Corporation. Global System Dynamics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Kane Biotech

CVE:KNE

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name. It also offers scalp care products under the DermaKB brand name; and wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, Aledex, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

OKYO Pharma

NASDAQ:OKYO

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial